PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Plus Therapeutics Inc (PSTV) is not a strong buy for a beginner, long-term investor at this moment. While the stock has some positive long-term potential with ongoing clinical developments, the current financial performance, lack of strong trading signals, and mixed analyst sentiment suggest waiting for clearer growth indicators or catalysts before investing.
The MACD is positive and expanding, indicating a slight bullish momentum. RSI is neutral at 45.941, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 0.245, with resistance at 0.274 and support at 0.217.
Analysts highlight potential synergies between CNSide and Reyobiq, as well as a catalyst-rich 2026 with ongoing clinical trials. The gross margin remains strong at 100%.
Revenue dropped by 4.05% YoY in Q3 2025, and EPS fell significantly by 89.19% YoY. The company has faced dilution from recent equity offerings, and there are no significant hedge fund or insider trading trends. Stock trend analysis suggests a potential decline in the short term.
In Q3 2025, revenue decreased by 4.05% YoY to $1,397,000. Net income improved by 53.90% YoY but remains negative at -$4,423,000. EPS dropped significantly by 89.19% YoY to -0.04, indicating continued financial struggles.
Analysts maintain a Buy rating but have lowered price targets recently due to dilution concerns. The price targets range from $1 to $2, reflecting cautious optimism about the company's long-term potential.
